AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
In this recent report published in the Journal of Glaucoma, researchers in Yamanashi, Japan conducted a study "To assess the long-term effects of latanoprost monotherapy on intraocular pressure (IOP) reduction in Japanese patients with glaucoma. Those enrolled were patients with glaucoma who had been treated on an outpatient basis for more than 5 years at the Glaucoma Outpatient Clinic of the University of Yamanashi Hospital, with only latanoprost ophthalmic Solution as the first drug of choice."
"Subjects who underwent treatment with a drug other than latanoprost, laser therapy, or Surgery were eliminated from the study, and IOP reduction by latanoprost, the dropout rate and causative reasons, and the types of additional therapy were assessed in a retrospective manner. Seventy-two patients (age: 68.3 +/- 13.0 y) were enrolled, including 40 men and 32 women for the checking of 72 eyes. There were 47 eyes with normal tension glaucoma (NTG) and 25 with primary open angle glaucoma (POAG). The mean duration of latanoprost monotherapy was 4.1 +/- 2.0 years (range: 5 mo to 7y, median: 4.0y). IOP reduction rates (cumulative dropout rates) relative to the mean IOP before the start of latanoprost monotherapy (17.8 +/- 3.4 mm Hg) were 11.5% (8.3%) 15.5% (8.30%) 13.0% (9.7%), 13.4% (13.9%) 13.5% (19.4%), and 10.6% (30.6%) at 6 months, I year, 2 years, 3 years, 4 years, and 5 years after the start of monotherapy, respectively. Although latanoprost demonstrated ...
Source: HighBeam Research, Studies from University of Yamanashi, Medical Department update...